Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 3Urogenital Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma 1Prostatic Neoplasms 1Peripheral Nervous System Diseases 1Neoplasms 1Monoclonal Gammopathy of Undetermined Significance 1Melanoma 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hypertension 1Head and Neck Neoplasms 1Diabetes Mellitus 1Depressive Disorder, Major 1Depression 1Colorectal Neoplasms 1Cardiovascular Diseases 1

Interventions

Gemcitabine 34pembrolizumab 26Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Fatty Acids, Omega-3 × Clear all
NCT01803711 2017-12-27

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

UConn Health

Phase 2/3 Terminated
6 enrolled 4 charts

Cardiovascular Diseases, Depression, Depressive Disorder, Major, Diabetes Mellitus, Hypertension, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡